BACKGROUND: A study was undertaken to investigate the detection of relapse and survival outcomes in @entity1 with @entity5 treated with curative intent chemoradiotherapy, and evaluated with a post-therapy @entity419 positron emission tomography (FDG-PET) scan. METHODS: Between January 2002 and June 2007, 105 consecutive @entity1 were prospectively enrolled into a registry study designed to assess outcomes of chemoradiotherapy. A FDG-PET scan was performed between 3 and 12 months (median, 4.9 months) post-treatment at clinician discretion. @entity5 response was graded as complete metabolic response, partial metabolic response, or progressive @entity209 . RESULTS: Median follow-up was 36 months. At post-therapy FDG-PET, 73 (70%) @entity1 had complete metabolic response, 10 (9%) had partial metabolic response, and 22 (21%) had progressive @entity209 . Overall survival at 3 years was 77% in all @entity1 , and 95% for those with complete metabolic response. On multivariate analysis, complete metabolic response (P < .0001) and pretreatment @entity5 volume (P = .041) were strong predictors for overall survival. The number of involved lymph nodes (P < .005) and International Federation of Gynecology and Obstetrics stage (P = .04) were predictive of relapse-free survival. In total, 18 @entity1 relapsed at a single site, and 13 underwent salvage, with a 3-year survival of 67%. @entity1 with complete metabolic response had a distant failure rate 36-fold less than those with partial metabolic response (P < .0001). After complete metabolic response, only 1 @entity1 (1.6%) relapsed without symptoms and was detected through physical examination. CONCLUSIONS: The presence of a complete metabolic response at post-therapy FDG-PET is a powerful predictor for survival after chemoradiation. The very low rate of recurrence in @entity1 with a complete metabolic response justifies a conservative follow-up approach for these @entity1 , because relapse is usually symptomatic and not detected by routine clinical review.

Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18) F-fluorodeoxyglucose'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'cervical cancer'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disease']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
